Photo of Elizabeth B. Lamont,  MD, MS

Elizabeth B. Lamont, MD, MS

Massachusetts General Hospital

Massachusetts General Hospital

Elizabeth B. Lamont, MD, MS

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Associate Professor, Health Care Policy, Harvard Medical School
  • Thoracic Oncologist, Hematology/Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a medical oncologist whose main academic endeavor is research in clinical epidemiology and health services research in cancer. My research examines factors that are biologically separate from cancer but that may nonetheless be important determinants of its presentation, diagnosis, treatment, and mortality. In this research, I strive to be innovative in at least two broad ways: first, by focusing on non-malignant factors that affect malignant disease treatment and outcome, and second by privileging a life-course perspective in oncology, thus examining the full trajectory of cancer from screening for an illness to death.

Publications

Powered by Harvard Catalyst
  • Kehl KL, Lamont EB, McNeil BJ, Bozeman SR, Kelley MJ, Keating NL. Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. 2015. PubMed
  • Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, . Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). Journal of the National Cancer Institute 2014; 107:336. PubMed
  • Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS. Genotyping Lung Cancer Is an Investment in the Future. J Clin Oncol 2014. PubMed
  • Lamont EB, Zaslavsky AM, Subramanian SV, Meilleur AE, He Y, Landrum MB. Elderly breast and colorectal cancer patients' clinical course: patient and contextual influences. Med Care 2014; 52:809-17. PubMed
  • Lamont EB, Yu M, He Y, Saltz L, Muss H, Zaslavsky AM, . Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). 2014. PubMed
  • Meilleur A, Subramanian SV, Plascak JJ, Fisher JL, Paskett ED, Lamont EB. Rural residence and cancer outcomes in the United States: issues and challenges. Cancer Epidemiol Biomarkers Prev 2013; 22:1657-67. PubMed
  • Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB. Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy. Cancer 2013; 119:691-9. PubMed
  • Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. Journal of the National Cancer Institute 2013; 105:113-21. PubMed
  • Lamont EB, He Y, Subramanian SV, Zaslavsky AM. Do socially deprived urban areas have lesser supplies of cancer care services? J Clin Oncol 2012; 30:3250-7. PubMed
  • Soerjomataram I, Thong MS, Ezzati M, Lamont EB, Nusselder WJ, van de Poll-Franse LV. Most colorectal cancer survivors live a large proportion of their remaining life in good health. Cancer Causes Control 2012; 23:1421-8. PubMed
  • Kouri EM, Landrum MB, Lamont EB, Bozeman S, McNeil BJ, Keating NL. Location of cancer surgery for older veterans with cancer. Health Serv Res 2012; 47:783-93. PubMed
  • Keating NL, Landrum MB, Lamont EB, Bozeman SR, McNeil BJ. Area-Level Variations in Cancer Care and Outcomes. Med Care 2012. PubMed
  • Lamont EB, Lan L. Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens. Med Care 2012. PubMed
  • Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, Brown JR, Earle CC, Rabin M, McNeil BJ. Survival of Older Patients With Cancer in the Veterans Health Administration Versus Fee-for-Service Medicare. J Clin Oncol 2012. PubMed
  • Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ, Keating NL. Understanding variation in primary prostate cancer treatment within the veterans health administration. Urology 2012; 79:537-45. PubMed
  • Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer 2011. PubMed
  • Gray SW, Landrum MB, Lamont EB, McNeil BJ, Jaklitsch MT, Keating NL. Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. Cancer 2011. PubMed
  • Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M, McNeil BJ. Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med 2011; 154:727-36. PubMed
  • Keating NL, Landrum MB, Lamont EB, Earle CC, Bozeman SR, McNeil BJ. End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer 2010; 116:3732-9. PubMed
  • Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 2010; 75:642-7. PubMed
  • Dow LA, Matsuyama RK, Ramakrishnan V, Kuhn L, Lamont EB, Lyckholm L, Smith TJ. Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol 2010; 28:299-304. PubMed
  • Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol 2010; 28:215-21. PubMed
  • Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J. Neurooncol. 2009; 95:427-31. PubMed
  • Lamont EB,Dias LE. Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study. Cancer J 2008; 14:276-7. PubMed
  • Warren JL,Yabroff KR,Meekins A,Topor M,Lamont EB,Brown ML. Evaluation of trends in the cost of initial cancer treatment. Journal of the National Cancer Institute 2008; 100:888-97. PubMed
  • Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. Journal of the National Cancer Institute 2008; 100:630-41. PubMed
  • Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care 2008; 46:303-8. PubMed
  • Lamont EB, Dias LE, Lauderdale DS. NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect? J Gen Intern Med 2007; 22:1166-71. PubMed
  • Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, Warren JL. Patient time costs associated with cancer care. Journal of the National Cancer Institute 2007; 99:14-23. PubMed
  • Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA,. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 2006; 98:1335-8. PubMed
  • Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments. Clin Cancer Res 2006; 12:3601s-5s. PubMed
  • Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly?: a case-control study of Medicare beneficiaries. Cancer 2006; 106:923-30. PubMed
  • Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 2005; 97:1080-3. PubMed
  • Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23:585-90. PubMed
  • Lamont EB. A demographic and prognostic approach to defining the end of life. J Palliat Med 2006; 8 Suppl 1:S12-21. PubMed
  • Gupta SK, Lamont EB. Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. J Am Geriatr Soc 2004; 52:1681-7. PubMed
  • Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 2003; 13:698-703. PubMed
  • Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 2003; 95:1370-5. PubMed
  • Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA 2003; 290:98-104. PubMed
  • Lamont EB, Christakis NA, Lauderdale DS. Favorable cardiac risk among elderly breast carcinoma survivors. Cancer 2003; 98:2-10. PubMed
  • Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20:3992-8. PubMed
  • Lamont EB, Christakis NA. Physician factors in the timing of cancer patient referral to hospice palliative care. Cancer 2002; 94:2733-7. PubMed
  • Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care 2002; 40:201-11. PubMed
  • Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med 2001; 134:1096-105. PubMed
  • Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2002; 2:261-9. PubMed
  • Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320:469-72. PubMed
  • Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999; 5:2289-96. PubMed
  • Lamont EB, Christakis NA. Some elements of prognosis in terminal cancer. Oncology (Huntingt) 1999; 13:1165-70; discussion 1172-. PubMed
Hide